Back to search

Peptide record

TPDB05298

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05298
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifp Antifungipept CAFPdb dbAMP 3.0 AI4AVP AVPpred-BWR CellPPD-MOD CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KWCFRVCYRGICYRRCR
Physicochemical Analysis
C99H154N34O20S4
ANDEQHLMPST
R
2268.77
10.10
6
0
6
+6
-1.01
-0.518
40.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
8730
384.79
6
Residue Composition
number
0
A
5
R
0
N
0
D
4
C
0
E
0
Q
1
G
0
H
1
I
0
L
1
K
0
M
1
F
0
P
0
S
0
T
1
W
2
Y
1
V
Amino Acid Distribution
A: 0 R: 5 N: 0 D: 0 C: 4 E: 0 Q: 0 G: 1 H: 0 I: 1 L: 0 K: 1 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 2 V: 1
Chemical Descriptors
17
C99H154N34O20S4
2268.77
10.10
+6
-1.01
-0.518
Evidence Records 88 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.8-3.1 µg/mL

Target

S. typhimurium LT2 or 1102

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeru
Evidence 2 Activity

Activity

MIC
Antibacterial
1.6-3.1 µg/mL

Target

Escherichia coli K12

Source & Reference

dbAMP DRAMP

Other

Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S.
Evidence 3 Activity

Activity

MIC
Antibacterial
1.6-3.1 µg/mL

Target

S. Minnesota 1114W or R595

Source & Reference

dbAMP DRAMP

Other

st Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml),
Evidence 4 Activity

Activity

MIC
Antibacterial
12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C.
Evidence 5 Activity

Activity

MIC
Antibacterial
3.1-6.3 µg/mL

Target

Staphylococcus aureus 209P or ATCC 25923

Source & Reference

dbAMP DRAMP

Other

l), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040
Evidence 6 Activity

Activity

MIC
Antibacterial
3.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

, P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albican
Evidence 7 Activity

Activity

MIC
Antibacterial
3.1 µg/mL

Target

Candida albicans M9

Source & Reference

dbAMP DRAMP

Other

ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. kruse
Evidence 8 Activity

Activity

MIC
Antibacterial
1.56 µg/mL

Target

C. neoformans IMF 40040

Source & Reference

dbAMP DRAMP

Other

923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MI
Evidence 9 Activity

Activity

MIC
Antibacterial
14.1 µM

Target

Candida albicans SC5314

Source & Reference

dbAMP DRAMP

Other

3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22
Evidence 10 Activity

Activity

MIC
Antibacterial
28.2 µM

Target

C. krusei IFM56881

Source & Reference

dbAMP DRAMP

Other

1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al.,
Evidence 11 Activity

Activity

MIC
Antibacterial
3.53 µM

Target

C. neoformans H99

Source & Reference

dbAMP DRAMP

Other

0040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by
Evidence 12 Activity

Activity

MIC
Antibacterial
7.05 µM

Target

C. parapsilosis ATCC22019

Source & Reference

dbAMP DRAMP

Other

s SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by binding to gp120 and CD4. More active aga
Evidence 13 Activity

Activity

MIC
Antifungal
0.8-3.1 µg/mL

Target

S. typhimurium LT2 or 1102

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeru
Evidence 14 Activity

Activity

MIC
Antifungal
1.6-3.1 µg/mL

Target

Escherichia coli K12

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S.
Evidence 15 Activity

Activity

MIC
Antifungal
1.6-3.1 µg/mL

Target

S. Minnesota 1114W or R595

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

st Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml),
Evidence 16 Activity

Activity

MIC
Antifungal
12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C.
Evidence 17 Activity

Activity

MIC
Antifungal
3.1-6.3 µg/mL

Target

Staphylococcus aureus 209P or ATCC 25923

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

l), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040
Evidence 18 Activity

Activity

MIC
Antifungal
3.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

, P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albican
Evidence 19 Activity

Activity

MIC
Antifungal
3.1 µg/mL

Target

Candida albicans M9

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. kruse
Evidence 20 Activity

Activity

MIC
Antifungal
1.56 µg/mL

Target

C. neoformans IMF 40040

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MI
Evidence 21 Activity

Activity

MIC
Antifungal
14.1 µM

Target

Candida albicans SC5314

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22
Evidence 22 Activity

Activity

MIC
Antifungal
28.2 µM

Target

C. krusei IFM56881

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al.,
Evidence 23 Activity

Activity

MIC
Antifungal
3.53 µM

Target

C. neoformans H99

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

0040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by
Evidence 24 Activity

Activity

MIC
Antifungal
7.05 µM

Target

C. parapsilosis ATCC22019

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

s SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by binding to gp120 and CD4. More active aga
Evidence 25 Activity

Activity

MIC
Antiparasitic
0.8-3.1 µg/mL

Target

S. typhimurium LT2 or 1102

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeru
Evidence 26 Activity

Activity

MIC
Antiparasitic
1.6-3.1 µg/mL

Target

Escherichia coli K12

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S.
Evidence 27 Activity

Activity

MIC
Antiparasitic
1.6-3.1 µg/mL

Target

S. Minnesota 1114W or R595

Source & Reference

dbAMP 3.0 DRAMP

Other

st Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml),
Evidence 28 Activity

Activity

MIC
Antiparasitic
12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C.
Evidence 29 Activity

Activity

MIC
Antiparasitic
3.1-6.3 µg/mL

Target

Staphylococcus aureus 209P or ATCC 25923

Source & Reference

dbAMP 3.0 DRAMP

Other

l), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040
Evidence 30 Activity

Activity

MIC
Antiparasitic
3.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

, P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albican
Evidence 31 Activity

Activity

MIC
Antiparasitic
3.1 µg/mL

Target

Candida albicans M9

Source & Reference

dbAMP 3.0 DRAMP

Other

ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. kruse
Evidence 32 Activity

Activity

MIC
Antiparasitic
1.56 µg/mL

Target

C. neoformans IMF 40040

Source & Reference

dbAMP 3.0 DRAMP

Other

923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MI
Evidence 33 Activity

Activity

MIC
Antiparasitic
14.1 µM

Target

Candida albicans SC5314

Source & Reference

dbAMP 3.0 DRAMP

Other

3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22
Evidence 34 Activity

Activity

MIC
Antiparasitic
28.2 µM

Target

C. krusei IFM56881

Source & Reference

dbAMP 3.0 DRAMP

Other

1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al.,
Evidence 35 Activity

Activity

MIC
Antiparasitic
3.53 µM

Target

C. neoformans H99

Source & Reference

dbAMP 3.0 DRAMP

Other

0040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by
Evidence 36 Activity

Activity

MIC
Antiparasitic
7.05 µM

Target

C. parapsilosis ATCC22019

Source & Reference

dbAMP 3.0 DRAMP

Other

s SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by binding to gp120 and CD4. More active aga
Evidence 37 Activity

Activity

MIC
Antiviral
0.8-3.1 µg/mL

Target

S. typhimurium LT2 or 1102

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeru
Evidence 38 Activity

Activity

MIC
Antiviral
1.6-3.1 µg/mL

Target

Escherichia coli K12

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S.
Evidence 39 Activity

Activity

MIC
Antiviral
1.6-3.1 µg/mL

Target

S. Minnesota 1114W or R595

Source & Reference

dbAMP 3.0 DRAMP

Other

st Gram- S. typhimurium LT2 or 1102 (MIC 0.8-3.1 ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml),
Evidence 40 Activity

Activity

MIC
Antiviral
12.5 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

ug/ml), E. coli K12 (MIC 1.6-3.1 ug/ml), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C.
Evidence 41 Activity

Activity

MIC
Antiviral
3.1-6.3 µg/mL

Target

Staphylococcus aureus 209P or ATCC 25923

Source & Reference

dbAMP 3.0 DRAMP

Other

l), S. Minnesota 1114W or R595 (MIC 1.6-3.1 ug/ml), P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040
Evidence 42 Activity

Activity

MIC
Antiviral
3.1 µg/mL

Target

B. subtilis

Source & Reference

dbAMP 3.0 DRAMP

Other

, P. aeruginosa (MIC 12.5 ug/ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albican
Evidence 43 Activity

Activity

MIC
Antiviral
3.1 µg/mL

Target

Candida albicans M9

Source & Reference

dbAMP 3.0 DRAMP

Other

ml), Gram+ S. aureus 209P or ATCC 25923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. kruse
Evidence 44 Activity

Activity

MIC
Antiviral
1.56 µg/mL

Target

C. neoformans IMF 40040

Source & Reference

dbAMP 3.0 DRAMP

Other

923 (MIC 3.1-6.3 ug/ml), B. subtilis (MIC 3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MI
Evidence 45 Activity

Activity

MIC
Antiviral
14.1 µM

Target

Candida albicans SC5314

Source & Reference

dbAMP 3.0 DRAMP

Other

3.1 ug/ml), C. albicans M9 (MIC 3.1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22
Evidence 46 Activity

Activity

MIC
Antiviral
28.2 µM

Target

C. krusei IFM56881

Source & Reference

dbAMP 3.0 DRAMP

Other

1 ug/ml), and C. neoformans IMF 40040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al.,
Evidence 47 Activity

Activity

MIC
Antiviral
3.53 µM

Target

C. neoformans H99

Source & Reference

dbAMP 3.0 DRAMP

Other

0040 (MIC 1.56 ug/ml). C. albicans SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by
Evidence 48 Activity

Activity

MIC
Antiviral
7.05 µM

Target

C. parapsilosis ATCC22019

Source & Reference

dbAMP 3.0 DRAMP

Other

s SC5314 (MIC 14.1 uM), C. krusei IFM56881(MIC 28.2 uM), C. neoformans H99 (MIC 3.53 uM), C. parapsilosis ATCC22019 (MIC 7.05 uM) ( Zhang et al., 2022 ). It also inhibits HIV by binding to gp120 and CD4. More active aga
Evidence 49 Activity

Activity

% Hemolysis
Hemolysis
9.6 72.8 %
[Ref.29870123] 9.6% hemolytic activity at 8 µg/mL and 72.8% hemolytic activity at 512 µg/mL against human red blood cells.

Target

human red blood cells

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Biochemistry 2002 41: 12359.##J Biochem. 1990 Aug 108(2):261-266.##Int J Mol Sci. 2019 Aug 26 20(17):4184.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 50 Activity

Activity

IC50
Toxicity
14.3±1.2 µM
Cytotoxic
IC50 | 14.3±1.2 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 51 Activity

Activity

IC50
Toxicity
9.4±1.1 µM
Cytotoxic
IC50 | 9.4±1.1 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 52 Activity

Activity

IC50
Toxicity
25.8±1.1 µM
Cytotoxic
IC50 | 25.8±1.1 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 53 Activity

Activity

IC50
Toxicity
9.9±1.1 µM
Cytotoxic
IC50 | 9.9±1.1 | µM | target cell: Human normal astrocytes

Target

Human normal astrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 54 Activity

Activity

IC50
Toxicity
23.7±1.1 µM
Cytotoxic
IC50 | 23.7±1.1 | µM | target cell: Human normal astrocytes

Target

Human normal astrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 55 Activity

Activity

55% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
55% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 56 Activity

Activity

28% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
28% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 57 Activity

Activity

20% Killing
Toxicity
100 µM
Cytotoxic
20% Killing | 100 | µM | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
Action mechanism of tachyplesin I and effects of PEGylation. | Biochim Biophys Acta | 2007
Evidence 58 Activity

Activity

28% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
28% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals | Exp Parasitol | 2008
Evidence 59 Activity

Activity

67% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
67% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. | Eur J Clin Microbiol Infect Dis | 2000
Evidence 60 Activity

Activity

10% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 100 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Deletion of all cysteines in tachyplesin I abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding. | Biochemistry | 2006
Evidence 61 Activity

Activity

25% Hemolysis
Toxicity
150 µg/mL
Hemolytic Cytotoxic
25% Hemolysis | 150 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Deletion of all cysteines in tachyplesin I abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding. | Biochemistry | 2006
Evidence 62 Activity

Activity

9.6% Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
9.6% Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 63 Activity

Activity

72.8% Hemolysis
Toxicity
512 µg/mL
Hemolytic Cytotoxic
72.8% Hemolysis | 512 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 64 Activity

Activity

IC50
Toxicity
27.0±1.2 µM
Cytotoxic
IC50 | 27.0±1.2 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 65 Activity

Activity

IC50
Toxicity
31.2±1.2 µM
Cytotoxic
IC50 | 31.2±1.2 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 66 Activity

Activity

IC50
Toxicity
12.1±1.1 µM
Cytotoxic
IC50 | 12.1±1.1 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 67 Activity

Activity

IC50
Toxicity
47.1±1.1 µM
Cytotoxic
IC50 | 47.1±1.1 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 68 Activity

Activity

IC50
Toxicity
17.5±1.1 µM
Cytotoxic
IC50 | 17.5±1.1 | µM | target cell: Human normal astrocytes

Target

Human normal astrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 69 Activity

Activity

IC50
Toxicity
27.0±1.3 µM
Cytotoxic
IC50 | 27.0±1.3 | µM | target cell: Human normal astrocytes

Target

Human normal astrocytes

Source & Reference

NA
DBAASP
Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I. | Bull Exp Biol Med | 2017
Evidence 70 Activity

Activity

50% Hemolysis
Toxicity
34.9±2.8 µM
Hemolytic Cytotoxic
50% Hemolysis | 34.9±2.8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties. | Int J Mol Sci | 2019
Evidence 71 Activity

Activity

50% Cell death
Toxicity
11.6±1.6 µM
Cytotoxic
50% Cell death | 11.6±1.6 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties. | Int J Mol Sci | 2019
Evidence 72 Activity

Activity

50% Cell death
Toxicity
40 µM
Cytotoxic
50% Cell death | 40 | µM | target cell: Chinese hamster ovary cells CHO-K1

Target

Chinese hamster ovary cells CHO-K1

Source & Reference

NA
DBAASP
Action mechanism of tachyplesin I and effects of PEGylation. | Biochim Biophys Acta | 2007
Evidence 73 Activity

Activity

50% Hemolysis
Toxicity
>100 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells. | Peptides | 2011
Evidence 74 Activity

Activity

50% Cell death
Toxicity
52.01±1.29 µg/mL
Cytotoxic
50% Cell death | 52.01±1.29 | µg/mL | target cell: Human dendritic cells

Target

Human dendritic cells

Source & Reference

NA
DBAASP
Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells. | Peptides | 2011
Evidence 75 Activity

Activity

<=10% Hemolysis
Toxicity
0.25 µg/mL
Hemolytic Cytotoxic
<=10% Hemolysis | 0.25 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-Activity and -Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1. | ACS Infect Dis | 2017
Evidence 76 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Structure-Activity and -Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1. | ACS Infect Dis | 2017
Evidence 77 Activity

Activity

IC50
Toxicity
23.5±1.2 µM
Cytotoxic
IC50 | 23.5±1.2 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III | Mar Drugs | 2018
Evidence 78 Activity

Activity

IC50
Toxicity
13±1.5 µM
Cytotoxic
IC50 | 13±1.5 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III | Mar Drugs | 2018
Evidence 79 Activity

Activity

IC50
Toxicity
24.7±1.8 µM
Cytotoxic
IC50 | 24.7±1.8 | µM | target cell: Human normal astrocytes

Target

Human normal astrocytes

Source & Reference

NA
DBAASP
Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III | Mar Drugs | 2018
Evidence 80 Activity

Activity

38% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
38% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III | Mar Drugs | 2018
Evidence 81 Activity

Activity

50% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
50% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure Elucidation and Functional Studies of a Novel β-hairpin Antimicrobial Peptide from the Marine Polychaeta Capitella teleta. | Mar Drugs | 2020
Evidence 82 Activity

Activity

50% Cell death
Toxicity
32-64 µM
Cytotoxic
50% Cell death | 32-64 | µM | target cell: Human embryonic fibroblasts

Target

Human embryonic fibroblasts

Source & Reference

NA
DBAASP
Structure Elucidation and Functional Studies of a Novel β-hairpin Antimicrobial Peptide from the Marine Polychaeta Capitella teleta. | Mar Drugs | 2020
Evidence 83 Activity

Activity

4.8% Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
4.8% Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 84 Activity

Activity

14.9% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
14.9% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 85 Activity

Activity

14.3% Hemolysis
Toxicity
8 µg/mL
Hemolytic Cytotoxic
14.3% Hemolysis | 8 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 86 Activity

Activity

20.5% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
20.5% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influences of disulfide connectivity on structure and antimicrobial activity of tachyplesin I. | J Pept Sci | 2018
Evidence 87 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.29870123] 9.6% hemolytic activity at 8 µg/mL and 72.8% hemolytic activity at 512 µg/mL against human red blood cells. | Cytotoxicity: [Ref.28429216]It possessed a cytotoxic effect on HL-60 cells (acutehuman promyelocytic leukemia cells) , K562 cells(myelogenous leukemia cells) , TSU cells (prostatecancer cells) .

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochemistry 2002 41: 12359.##J Biochem. 1990 Aug 108(2):261-266.##Int J Mol Sci. 2019 Aug 26 20(17):4184.
Evidence 88 Hemolysis

Activity

9.6 72.8 %
% Hemolysis
[Ref.29870123] 9.6% hemolytic activity at 8 µg/mL and 72.8% hemolytic activity at 512 µg/mL against human red blood cells.
Hemolysis

Target

human red blood cells

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Biochemistry 2002 41: 12359.##J Biochem. 1990 Aug 108(2):261-266.##Int J Mol Sci. 2019 Aug 26 20(17):4184.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.